Identify the Risk of Acute Kidney Injury—Before It’s a Problem
The NephroCheck Test was created for use alongside clinical evaluation of critically ill patients over 21. With results in just 20 minutes, the test is intended to assist the clinician in assessing the risk of moderate to severe acute kidney injury in the next 12 hours.
Identify, Stratify and Mitigate
the Risk of Acute Kidney Injury
Why is early identification of AKI important?
Dr. Peter McCullough discusses how early identification is fundamental for treating acute kidney injury. The NephroCheck Test can help inform certain adjustments to critical care management.
Identifying AKI Biomarkers
The NephroCheck Test is designed to detect the presence of two key biomarkers, allowing health care professionals to assess the risk of acute kidney injury earlier and potentially mitigate severe consequences.3
A Renal “Alarm System”
The NephroCheck Test produces a single numerical AKIRisk Score. Two cutoffs, selected in consultation with global experts, were judged to be clinically appropriate for the intended use.4,5
(AKIRisk Score = 0.3)
A low cutoff was chosen that allows early recognition of the majority of patients who will develop AKI.*
- This cutoff was selected to have high sensitivity for the primary end point and with the intent to be used in routine clinical practice to identify patients who are at high risk for AKI.
- These candidates should receive kidney-sparing management strategies, such as those outlined in the KDIGO guidelines for high-risk patients.5
(AKIRisk Score = 2.0)
A high cutoff was also selected to allow identification of patients who will develop AKI with high specificity.
- This cutoff was selected to identify the subgroup of patients who are at the highest risk of AKI.*
- It can be considered for more active interventions when clinically appropriate.5
*Moderate to severe AKI in the next 12 hours.
The NephroCheck Test AKIRisk Score Is Linked to Outcomes6
The NephroCheck Test AKIRisk Score Predicts Death or Dialysis Within Nine Months7
The NephroCheck Test remains a statistically significant predictor of death or dialysis after adjustment for disease severity (APACHE III) and serum creatinine.
Postoperative Biomarker-Guided Management Strategy
A recent review in Nephrology Dialysis Transplant8 addresses the use of the NephroCheck Test in a biomarker-guided patient management strategy based on KDIGO guidelines.
Proposed clinical application of risk assessment for patients immediately after cardiac surgery. STS, Society of Thoracic Surgery; I/O, input and output; SCr, serum creatinine; CVP, central venous pressure; NSAIDs, non-steroidal anti-inflammatory drugs; ACE, angiotensin converting enzyme inhibitor; SCVO2, central venous oxygen saturation; h/o, history of; LV Fx, left ventricular function; PA, pulmonary artery; CI, cardiac index.